- Count Deutsche Bank and Morgan Stanley among those not too concerned with Neurocrine Biosciences' (NBIX) Phase 2 NBI-98854 whiff which has the shares trading 31% lower AH.
- The rationale behind staying upbeat: It's all about the Endometriosis treatment elagolix, which Robyn Karnauskas says has potential in uterine fibroids as well.
- From Morgan: "... thinking weakness will get gobbled up ... as the Endometriosis story seems to be the main driver of the stock."
- From Deutsche: "With no VMAT we see fair value of NBIX in the $13-18 range."
Morgan, Deutsche brush off Neurocrine Bio's VMAT miss
Sep 9 2013, 17:30 ET